Compare Brunswick Corporation (BC) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Cassava Sciences Inc — how do they compare? Brunswick Corporation trades at $77.96 (market cap $5.04B), while Cassava Sciences Inc trades at $1.1 (market cap $52.66M). The key difference: Brunswick Corporation is far larger — about 95.7× Cassava Sciences Inc's market cap, and Brunswick Corporation pays a 2.27% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BC | FLNA | |
|---|---|---|
Market Cap | $5.04B | $52.66M |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $4.64 |
52-Week Low | $56.64 | $1.09 |
Enterprise Value | $7.20B | -$33.92M |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BC's stock trades at $76.95, down 1.22% on the day, with a bearish technical signal and support near $76. The company reported a net loss of $137.30 million in 2025 despite revenue of $5.36 billion, though recent earnings beat expectations. Analyst consensus is strongly bullish with a $86.40 price target, and the company continues expanding its Freedom Boat Club business.
The outlook is mixed: strong analyst support and operational cash flow of $562.10 million in 2025 provide upside potential, but negative profit margins and high P/E of 73.92 pose valuation risks. Investors face headwinds from profitability challenges despite positive sentiment from Wall Street.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
